As the second generation sequencing (NGS) technology and its cost is reduced, and the governments in the asia-pacific region is becoming more and more attention of precision medical NGS have the opportunity to make the diagnosis and treatment of tumor diseases decision paradigm shift.
To do this, you also need to develop effective and accord with the actual situation of the market strategy, national policy emphasizes the value of the NGS technology and high quality to the pressing needs of the quality assurance and standardization.
APACMed held in May 2022, two regional and international levels of the roundtable, was invited to attend the experts including oncologists, pathologists, geneticists, regulators/policymakers and industry experts.
After extensive discussions, roundtable participants reached the consensus of opinion on how to ensure the quality of NGS test, all the markets in the asia-pacific region is dedicated to provide you with practical advice.At the same time, the minimum quality standards, must consider the regulatory policy differences in different areas.
In addition to the quality, the roundtable participants also stressed that there are several factors in the existing medical system hindered the NGS reach their true potential, these factors will become the focus of attention in the future, for example: NGS to detect the lack of health coverage, leading to pay high cost, market access is difficult;Doctors consciousness lack;Match the availability/low coverage of treatment.
Guarantee the quality of NGS detection is the first step, which is the most basic step, it can be expected only for NGS market access to lay a more solid foundation, and ultimately provide a better treatment for cancer patients.
01192023090116